Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01103778 · ClinicalTrials.gov registry record · Phase 4
Pilot Study of Velcade® in IgA Nephropathy
A Phase 4 study, sponsored by The Rogosin Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
NCT01103778: Completed Phase 4 study, sponsored by The Rogosin Institute.
NCT01103778 is a Phase 4 study that has completed, run by The Rogosin Institute. The registered enrollment target is 11 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01103778, a Phase 4 study, has completed, sponsored by The Rogosin Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
Study Summary
The primary objective of this study is to investigate the ability of Velcade® (bortezomib) to induce complete or partial remission in patients with severe IgA nephropathy. The secondary objectives are to assess clinical outcomes relating to safety and efficacy, such as infection, malignancy, preservation of renal function, partial responders, relapse rate, and to study mechanistic assays to predict remission.
Primary Outcome
Quantification of urinary protein will be made after treatment by measuring 24 hr urine protein.
Interventions
- DRUG Bortezomib (Velcade®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2010-07 |
| Est. Completion | 2017-04-17 |
| Phase | Phase 4 |
What the finished NCT01103778 record still lists
NCT01103778 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Bortezomib (Velcade®) is the first listed.
NCT01103778 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01103778 about?
NCT01103778 is a clinical study titled "Pilot Study of Velcade® in IgA Nephropathy". The primary objective of this study is to investigate the ability of Velcade® (bortezomib) to induce complete or partial remission in patients with severe IgA nephropathy. The secondary objectives are to assess clinical outcomes relating to safety and efficacy, such as infection, malignancy, preser...
What is the current status of trial NCT01103778?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2010-07. Estimated completion is 2017-04-17.
What interventions are being tested in trial NCT01103778?
The interventions under investigation include: Bortezomib (Velcade®) (DRUG).
Who is sponsoring clinical trial NCT01103778?
This trial is sponsored by The Rogosin Institute, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01103778's enrollment target sits among peer trials
11 1931st of 2000 higher than 61 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia